US Stock Insider Trading | Omeros Corporation disclosed two insider trading transactions on February 20

K-LinePoet · 2026-02-22T01:17:25+00:00

Omeros Corporation recently disclosed insider trading activity, with Director Demopulos Gregory A MD purchasing 400,000 shares and selling 357,700 shares on February 18. The company focuses on the development of treatments related to the complement system, aiming to enhance immune system function.

K-LinePoet

2026-02-22 01:17:25

Abstract generation in progress

On February 20, 2026, Omeros Corporation (OMER) disclosed two insider trading transactions. Director Demopulos Gregory A MD purchased 400,000 shares on February 18, 2026.

【Recent Insider Transactions】

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
February 20, 2026	Director	Demopulos Gregory A MD	February 18, 2026	Sell	357,700	11.93	4,267,100
February 20, 2026	Director	Demopulos Gregory A MD	February 18, 2026	Buy	400,000	10.27	4,108,000
January 14, 2026	Executive	Borges David J.	January 13, 2026	Buy	30,000	3.06	91,800
January 14, 2026	Executive	Borges David J.	January 12, 2026	Sell	30,000	12.72	381,600
January 14, 2026	Executive	Borges David J.	January 13, 2026	Sell	30,000	12.31	369,300
November 21, 2023	Executive	Demopulos Gregory A MD	November 17, 2023	Buy	15,000	1.68	25,200
November 17, 2023	Director	Demopulos Peter A MD	November 15, 2023	Buy	10,000	1.53	15,300
November 15, 2023	Executive	Demopulos Gregory A MD	November 14, 2023	Buy	25,000	1.44	36,000
November 15, 2023	Executive	Demopulos Gregory A MD	November 13, 2023	Buy	37,500	1.29	48,400
September 14, 2023	Director	Bumol Thomas F.	September 12, 2023	Buy	10,000	3.31	33,100

【Company Information】

Omeros Corporation was founded in Washington. The company is advancing multiple development projects focused on diseases and disorders related to the complement system, a group of specialized proteins that prevent invasive pathogens and damaged cells within the body. The complement system is a crucial part of the human immune system. When triggered, various components of the complement system work together to produce immune responses, fight infections, and clear damaged or dead cells, maintaining the health of bodily systems. However, dysregulation of the complement system—either overactivation or underactivation—can be harmful and is associated with increased vulnerability to infectious and non-infectious diseases, including autoimmune diseases, chronic inflammation, thrombotic microangiopathies, and cancer.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.